Literature DB >> 33484495

Paraoxonase-1 (PON1) Status Analysis Using Non-Organophosphate Substrates.

Judit Marsillach1, Rebecca J Richter2, Lucio G Costa1,3, Clement E Furlong2,4.   

Abstract

Human paraoxonase-1 (PON1) is a high-density lipoprotein-associated enzyme with antioxidant, anti-inflammatory, and antiapoptotic roles. The ability of PON1 to hydrolyze specific organophosphate (OP) compounds and prevent accumulation of oxidized lipids in lipoproteins has prompted a large number of studies investigating PON1's role in modulating toxicity and disease. Most of these studies, however, have only focused on PON1 single nucleotide polymorphism analyses and have ignored PON1 activity levels, arguably the most important parameter in determining protection against exposure and disease. We developed a two-substrate activity assay termed "PON1 status" that reveals both the functional PON1192 genotype and plasma PON1 activity levels. While our previous studies with PON1 status demonstrated that both PON1192 functional genotype and enzymatic activity levels obtained exclusively by determining PON1 status are required for a proper evaluation of PON1's role in modulating OP exposures and risk of disease, the original PON1 status assay requires the use of highly toxic OP metabolites. As many laboratories are not prepared to handle such toxic compounds and the associated waste generated, determination of PON1 status has been limited to rather few studies. Here, we describe a PON1 status protocol that uses non-OP substrates with a resolution equivalent to that of the original PON1 status approach. We have also included useful suggestions to ensure the assays can easily be carried out in any laboratory. The protocols described here will enable a proper examination of the risk of exposure or susceptibility to disease in PON1 epidemiological studies without the need to handle highly toxic substrates.
© 2021 Wiley Periodicals LLC. Basic Protocol: Determining PON1 status using non-organophosphate substrates Support Protocol 1: Experimental pathlength determination Support Protocol 2: PON1 DNA genotyping for the Q192R (rs662) polymorphism. © 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  PON1 activity assay; PON1 status; non-organophosphate substrates; paraoxonase-1

Mesh:

Substances:

Year:  2021        PMID: 33484495      PMCID: PMC7924808          DOI: 10.1002/cpz1.25

Source DB:  PubMed          Journal:  Curr Protoc        ISSN: 2691-1299


  61 in total

1.  Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype.

Authors:  G P Jarvik; L S Rozek; V H Brophy; T S Hatsukami; R J Richter; G D Schellenberg; C E Furlong
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-11       Impact factor: 8.311

2.  Serum esterases. I. Two types of esterase (A and B) hydrolysing p-nitrophenyl acetate, propionate and butyrate, and a method for their determination.

Authors:  W N ALDRIDGE
Journal:  Biochem J       Date:  1953-01       Impact factor: 3.857

Review 3.  Human PON1, a biomarker of risk of disease and exposure.

Authors:  C E Furlong; S M Suzuki; R C Stevens; J Marsillach; R J Richter; G P Jarvik; H Checkoway; A Samii; L G Costa; A Griffith; J W Roberts; D Yearout; C P Zabetian
Journal:  Chem Biol Interact       Date:  2010-03-23       Impact factor: 5.192

4.  Comparison of paraoxonase 1 measurements in serum and in lithium-heparin-anticoagulated plasma samples.

Authors:  Natàlia Ferré; Jordi Camps; Judit Marsillach; Bharti Mackness; Mike Mackness; Blai Coll; Mònica Tous; Jorge Joven
Journal:  Clin Chem       Date:  2005-05       Impact factor: 8.327

Review 5.  Pharmacological and dietary modulators of paraoxonase 1 (PON1) activity and expression: the hunt goes on.

Authors:  Lucio G Costa; Gennaro Giordano; Clement E Furlong
Journal:  Biochem Pharmacol       Date:  2010-11-18       Impact factor: 5.858

6.  Toxicity of chlorpyrifos and chlorpyrifos oxon in a transgenic mouse model of the human paraoxonase (PON1) Q192R polymorphism.

Authors:  Toby B Cole; Betsy J Walter; Diana M Shih; Aaron D Tward; Aldons J Lusis; Charles Timchalk; Rebecca J Richter; Lucio G Costa; Clement E Furlong
Journal:  Pharmacogenet Genomics       Date:  2005-08       Impact factor: 2.089

7.  The human serum paraoxonase/arylesterase polymorphism.

Authors:  H W Eckerson; C M Wyte; B N La Du
Journal:  Am J Hum Genet       Date:  1983-11       Impact factor: 11.025

8.  Immunohistochemical analysis of paraoxonases-1 and 3 in human atheromatous plaques.

Authors:  Judit Marsillach; Jordi Camps; Raul Beltran-Debón; Anna Rull; Gerard Aragones; Carmen Maestre-Martínez; Fàtima Sabench; Mercè Hernández; Daniel D Castillo; Jorge Joven; Mike Mackness; Bharti Mackness
Journal:  Eur J Clin Invest       Date:  2010-10-21       Impact factor: 4.686

9.  Effects of 5' regulatory-region polymorphisms on paraoxonase-gene (PON1) expression.

Authors:  V H Brophy; R L Jampsa; J B Clendenning; L A McKinstry; G P Jarvik; C E Furlong
Journal:  Am J Hum Genet       Date:  2001-05-02       Impact factor: 11.025

10.  Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein.

Authors:  M I Mackness; S Arrol; P N Durrington
Journal:  FEBS Lett       Date:  1991-07-29       Impact factor: 4.124

View more
  1 in total

1.  The Removal of Time-Concentration Data Points from Progress Curves Improves the Determination of Km: The Example of Paraoxonase 1.

Authors:  Boštjan Petrič; Marko Goličnik; Aljoša Bavec
Journal:  Molecules       Date:  2022-02-15       Impact factor: 4.411

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.